These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 15551196)
21. In vitro effects of St. John's wort extract and hyperforin on 5 HT uptake and efflux in human blood platelets. Uebelhack R; Franke L Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S146-7. PubMed ID: 11518065 [No Abstract] [Full Text] [Related]
22. Mechanism of action of St John's wort in depression : what is known? Butterweck V CNS Drugs; 2003; 17(8):539-62. PubMed ID: 12775192 [TBL] [Abstract][Full Text] [Related]
23. Effects of two different extracts of St. John's wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. Nöldner M; Chatterjee S Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S108-10. PubMed ID: 11518056 [TBL] [Abstract][Full Text] [Related]
24. The main components of St John's Wort inhibit low-density lipoprotein atherogenic modification: a beneficial "side effect" of an OTC antidepressant drug? Laggner H; Schreier S; Hermann M; Exner M; Mühl A; Gmeiner BM; Kapiotis S Free Radic Res; 2007 Feb; 41(2):234-41. PubMed ID: 17364950 [TBL] [Abstract][Full Text] [Related]
25. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790 [TBL] [Abstract][Full Text] [Related]
26. Hyperforin and its analogues inhibit CYP3A4 enzyme activity. Lee JY; Duke RK; Tran VH; Hook JM; Duke CC Phytochemistry; 2006 Dec; 67(23):2550-60. PubMed ID: 17083953 [TBL] [Abstract][Full Text] [Related]
27. St. John's wort extracts and some of their constituents potently inhibit ultimate carcinogen formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Schwarz D; Kisselev P; Roots I Cancer Res; 2003 Nov; 63(22):8062-8. PubMed ID: 14633740 [TBL] [Abstract][Full Text] [Related]
28. In vitro photochemical and phototoxicological characterization of major constituents in St. John's Wort (Hypericum perforatum) extracts. Onoue S; Seto Y; Ochi M; Inoue R; Ito H; Hatano T; Yamada S Phytochemistry; 2011 Oct; 72(14-15):1814-20. PubMed ID: 21782201 [TBL] [Abstract][Full Text] [Related]
29. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study. Wright CW; Gott M; Grayson B; Hanna M; Smith AG; Sunter A; Neill JC J Psychopharmacol; 2003 Dec; 17(4):403-8. PubMed ID: 14870952 [TBL] [Abstract][Full Text] [Related]
30. Hyperforin in St. John's wort drug interactions. Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470 [TBL] [Abstract][Full Text] [Related]
31. Hyperforin a constituent of St John's wort (Hypericum perforatum L.) extract induces apoptosis by triggering activation of caspases and with hypericin synergistically exerts cytotoxicity towards human malignant cell lines. Hostanska K; Reichling J; Bommer S; Weber M; Saller R Eur J Pharm Biopharm; 2003 Jul; 56(1):121-32. PubMed ID: 12837490 [TBL] [Abstract][Full Text] [Related]
32. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier. El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454 [TBL] [Abstract][Full Text] [Related]
33. Antidepressant activity of hyperforin conjugates of the St. John's wort, Hypericum perforatum Linn.: an experimental study. Muruganandam AV; Bhattacharya SK; Ghosal S Indian J Exp Biol; 2001 Dec; 39(12):1302-4. PubMed ID: 12018529 [TBL] [Abstract][Full Text] [Related]
34. Clinical risks of St John's Wort (Hypericum perforatum) co-administration. Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074 [TBL] [Abstract][Full Text] [Related]
35. Involvement of serotoninergic 5-HT1A/2A, alpha-adrenergic and dopaminergic D1 receptors in St. John's wort-induced prepulse inhibition deficit: a possible role of hyperforin. Tadros MG; Mohamed MR; Youssef AM; Sabry GM; Sabry NA; Khalifa AE Behav Brain Res; 2009 May; 199(2):334-9. PubMed ID: 19136030 [TBL] [Abstract][Full Text] [Related]
36. St. John's wort. Lawvere S; Mahoney MC Am Fam Physician; 2005 Dec; 72(11):2249-54. PubMed ID: 16342849 [TBL] [Abstract][Full Text] [Related]
38. Modulation of Pgp function by boswellic acids. Weber CC; Reising K; Müller WE; Schubert-Zsilavecz M; Abdel-Tawab M Planta Med; 2006 May; 72(6):507-13. PubMed ID: 16773534 [TBL] [Abstract][Full Text] [Related]
39. Effects of the antidepressant St. John's wort (Hypericum perforatum) on rat and human vas deferens contractility. Capasso R; Borrelli F; Montanaro V; Altieri V; Capasso F; Izzo AA J Urol; 2005 Jun; 173(6):2194-7. PubMed ID: 15879886 [TBL] [Abstract][Full Text] [Related]
40. NMDA receptor-antagonistic properties of hyperforin, a constituent of St. John's Wort. Kumar V; Mdzinarishvili A; Kiewert C; Abbruscato T; Bickel U; van der Schyf CJ; Klein J J Pharmacol Sci; 2006 Sep; 102(1):47-54. PubMed ID: 16936454 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]